Recent updates from the White House have announced a major change in Medicare coverage policies that will benefit millions struggling with obesity. Beginning soon, Medicare will cover certain GLP-1 receptor agonists—such as Wegovy and ZepBound—which are medications approved for weight management. This new coverage comes after negotiated deals ensuring these obesity drugs will cost beneficiaries as little as $149, dramatically lowering financial barriers. Eligibility for coverage will depend on specific medical criteria, including body mass index (BMI) thresholds and the presence of obesity-related health conditions. Proposed coverage criteria include a BMI over 35, or a BMI over 30 combined with at least one comorbidity, such as type 2 diabetes, hypertension, or metabolic risk factors typically associated with obesity. Additionally, individuals with a BMI over 27 plus metabolic risks may also qualify. This policy is designed not only to reduce the economic burden of obesity but also to improve public health outcomes by increasing access to effective weight loss therapies. The drugs covered, especially GLP-1 medications, have shown promising results in helping patients reduce weight and manage associated health risks. However, experts note that while Medicare coverage will greatly improve access, patients and healthcare providers must still work together to ensure eligibility criteria are met and that these therapies are used as part of comprehensive obesity management plans including lifestyle changes. Medicare beneficiaries interested in these medications should consult their healthcare providers to understand if they meet the criteria and to discuss the best course of treatment. With these new measures, the hope is that more individuals can gain support to manage obesity with cutting-edge medications covered by Medicare, making effective treatment more affordable and accessible.